Dr. Jose E. Najera Jr., MD

Dr. Najera practices at Memorial Health System of Southwest Oklahoma in Lawton, Oklahoma, part of Memorial Health System of Southwest Oklahoma.

Dr. Najera's NPI, 1760667851, was assigned on January 8, 2008. Dr. Najera holds Oklahoma license 29622.

Dr. Najera's primary practice is Memorial Health System of Southwest Oklahoma, at 3401 West Gore Blvd, Lawton, OK 73505 in Comanche County. The practice phone is (580) 355-8620.

Dr. Najera's primary practice is Memorial Health System of Southwest Oklahoma in Lawton, Oklahoma, part of Memorial Health System of Southwest Oklahoma. Dr. Najera is also affiliated with Orlando Regional Medical Center. The medical group on file is Cancer Centers of Southwest Oklahoma. Dmand AI also links Dr. Najera to 3 more hospitals, 2 group practices and clinics, 1 community health center and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Najera practices, 8 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Najera's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Najera is licensed in Oklahoma.

CMS data shows 1,424 Medicare services from Dr. Najera across 4 procedure codes in 2024, all of them office visits, for 510 Medicare patients. Medicare paid $107,255 for them.

CMS counts 510 Medicare patients who saw Dr. Najera in 2024. The largest group is 65 to 74, with 227 patients. 75% of them have high blood pressure, and 70% have high cholesterol. 10% are also on Medicaid. Their average risk score is 1.92, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Najera's median patient age at 69, with 63% women.

In 2024, Dr. Najera wrote 1,702 Medicare Part D claims for 260 patients. 76% of them were for generic drugs. CMS names the drug for 1,276 of them, across 45 drugs with 11 or more claims each, at $4,129,034 in total drug cost. In 2023, CMS named 1,260 claims across 42 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 77 out of 100 for Dr. Najera for performance year 2024, reported as part of a group. Dr. Najera accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Najera as offering telehealth.

Dmand AI links 2 papers to Dr. Najera, published from 2012 to 2021. Dr. Najera's most frequent co-authors are Kerin Bess Adelson, MD, Howard A. Burris, MD and Davey B. Daniel, MD.

Dmand AI links Dr. Najera to 6 clinical trials, 3 of them phase 3 studies. 3 are still active or recruiting. Conditions studied include Breast Neoplasms, Breast Diseases and Carcinoma, Ductal. Alliance Foundation Trials, LLC. sponsors the most, 2.

CMS Open Payments shows 1,199 general payments to Dr. Najera from 80 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 94% of the total. Pfizer Inc. paid the most, $1,926.